A Study of SGN-B7H4V in Advanced Solid Tumors
Clinicaltrials.gov ID
NCT05194072
Status
Recruiting
Study Type
Interventional, Phase 1
Sponsor
Seagen Inc.
Start Date
11 janvier 2022
Anticipated End Date
29 juin 2025
Study Contact
About the Study
This study will test the safety of a drug called SGN-B7H4V in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease.
Conditions
Ovarian Neoplasms
Peritoneal Neoplasms
Fallopian Tube Neoplasms
Triple Negative Breast Neoplasms
HER2 Negative Breast Neoplasms
Hormone Receptor Positive Breast Neoplasms
Endometrial Neoplasms
Carcinoma, Non-Small-Cell Lung
Cholangiocarcinoma
Gallbladder Carcinoma
Adenoid Cystic Carcinoma
Inclusion/Exclusion Criteria?
Primary, Secondary, Other Outcome Measures??
Locations in Canada
The Ottawa Hospital, Ottawa, Ontario, K1H 8L6, Canada
About the Study
This study will test the safety of a drug called SGN-B7H4V in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease.
Conditions
Ovarian Neoplasms
Peritoneal Neoplasms
Fallopian Tube Neoplasms
Triple Negative Breast Neoplasms
HER2 Negative Breast Neoplasms
Hormone Receptor Positive Breast Neoplasms
Endometrial Neoplasms
Carcinoma, Non-Small-Cell Lung
Cholangiocarcinoma
Gallbladder Carcinoma
Adenoid Cystic Carcinoma
Interventions
DRUG:
SGN-B7H4V
Locations in Canada
The Ottawa Hospital, Ottawa, Ontario, K1H 8L6, Canada